Pre-Test Navigating the Potential for a New Standard of Care for Previously Undiagnosed DLBCL Pre-Test 1. Which of the following is a preferred treatment regimen for 1L DLBCL in patients with Stage II (with extensive mesenteric disease) or Stage III-IV as recommended in the NCCN Guidelines Version 5.2023? DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + rituximab Pola-R-CHP (polatuzumab vedotin-piiq, rituximab, cyclophosphamide, doxorubicin, prednisone) RCDOP (rituximab, cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) Unsure 2. Which of the following is true regarding the timing of HD-MTX CNS prophylaxis in DLBCL patients at high risk of CNS relapse? End of treatment HD-MTX did not increase the risk of CNS relapse compared with intercalated delivery and caused fewer delays to R-CHOP therapy End of treatment HD-MTX increased the risk of CNS relapse compared with intercalated delivery and caused fewer delays to R-CHOP therapy End of treatment HD-MTX did not increase risk of CNS relapse compared with intercalated delivery and caused more delays to R-CHOP therapy End of treatment HD-MTX increased the risk of CNS relapse compared with intercalated delivery and caused more delays to R-CHOP therapy Unsure 3. Which of the following is true regarding the addition of ibrutinib to mini-R-CHOP in “very elderly” patients with DLBCL? 2-year PFS 40%, 2-year OS 48%, ORR 51% 2-year PFS 50%, 2-year OS 58%, ORR 61% 2-year PFS 60%, 2-year OS 68%, ORR 71% 2-year PFS 70%, 2-year OS 78%, ORR 81% Unsure How confident are you in your ability to Implement strategies to mitigate, monitor, and manage AEs and toxicities associated with newer/emerging first-line DLBCL treatment options? Very Confident Confident Somewht confident Not very confident Not at all confident
